Alzheimer Dis Assoc Disord. 2012 Jul 2. [Epub ahead of print]
Rivastigmine Patch Ameliorates Depression in Mild AD : Preliminary Evidence From a 6-Month Open-label Observational Study.
*IRCCS Santa Lucia Foundation †INRCA ‡Department of Neurological Sciences, University La Sapienza §Department of Neurological Science, San Giovanni Hospital ∥Department of Neuroscience, University “Tor Vergata,” Rome, Italy.
Here we investigated the effect of the rivastigmine patch alone on depression in 50 mild Alzheimer’s Disease (AD) patients with comorbid major depressive episode (MDE). First diagnosis acetyl-cholinesterase inhibitor and psychoactive drug-free outpatients (n=50) were recruited in memory clinics and reassessed after 3 and 6 months. Global cognitive functioning, depressive symptoms and MDE frequency were evaluated with the Mini Mental State Examination, the CERAD Dysphoria scale and the modified DSM-IV criteria for MDE in AD. MDE frequency reduced significantly from the first diagnostic visit (100%) to the 6-month follow-up (62%). We also found a significant reduction in CERAD Dysphoria scores that decreased from 6.2±3.9 mean±standard deviation to 4.9±4.5 at the 6-month follow-up. In AD patients with MDE rivastigmine alone can have a positive impact on depressive phenomena. Thus, future controlled study are justified to definitively verify if rivastigmine alone may improve depression in AD.
PMID: 22760171 PubMed – as supplied by publisher